ARID1A and non-Hodgkin lymphoma: In this study, the incidence of ARID1A was higher in r/r MB-NHL patients than in IR patients (35% vs. 7%), indicating that ARID1A mutations are enriched in resistant disease and that these patients might be insensitive to initial chemotherapy.